The Clinical Data Interchange Standards Consortium
(CDISC) is pleased to announce its collaboration with
DIA
and
Integrating the Healthcare Enterprise
(IHE) to bring a demonstration of the implementation of electronic health records (EHRs) to streamline medical research. This process represents a simple yet powerful means towards shortening the current 17 year gap in translating research results into clinical care decisions.
“CDISC has been a leader in demonstrating the value of EHRs in the research arena,” stated Dr. Doug Fridsma, Director, Office of Interoperability & Standards at the U.S. HHS Office of the National Coordinator for Health IT (ONC). “Linking clinical care with clinical research sets the stage for novel ways of leveraging patient care information using more granular metadata approaches.”
The currently available solution is being demonstrated by EHR vendors along with clinical trial technology and service providers, CDISC and HIMSS at DIA 2011 in Chicago on June 19-23.
DIA 2011 provides educational and networking opportunities to more than 8,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products.
“We are very pleased to partner with DIA and CDISC to feature the profiles from the Quality Research and Public Health domain of IHE. This is a valuable opportunity to share the HIMSS Interoperability ShowcaseTM with research stakeholders,” said H. Stephen Lieber, CAE, HIMSS President and CEO of HIMSS.
CDISC has been working with the IHE Committee on Quality Research and Public Health (QRPH) for the past 7 years to develop the necessary integration profiles to implement global standards such as CDISC and HL7. The ANSI-sponsored Interoperability Specification (IS # 158), which provides a core standard research dataset from EHRs, was ratified by the Health Information Technology Standards Panel (HITSP) in 2010. The development of this IS was conducted in a manner to ensure compliance with regulatory requirements for electronic source data, electronic record retention, patient privacy and data security, audit trails and the global Good Clinical Practices (GCP). The concept behind this standards-based innovation is that data should be entered once for multiple purposes, thus improving quality and patient safety along with streamlining workflow such that a busy clinician can readily participate in research.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.